Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2026 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungenAcceptable Use
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to Reports
Fundraising

Mylan

Mylan Raises $15B in Public

1000 Mylan Boulevard, Canonsburg, PA 15317January 1, 20242 min read
Employees
35000+

Mylan Raises $15B in Public


Mylan has successfully raised $15B in a Public at a $18B valuation led by Viatris.


Company Overview


Mylan is a Pharmaceuticals company headquartered in 1000 Mylan Boulevard, Canonsburg, PA 15317, founded in 1961 with 35000+ employees.


Generic pharmaceutical company


Fundraising Details


  • Amount Raised: $15B
  • Round Type: Public
  • Valuation: $18B
  • Date: 2024-01-01
  • Investors: Viatris

About Mylan


Generic pharmaceutical company The company is positioned in the Pharmaceuticals sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 1000 Mylan Boulevard, Canonsburg, PA 15317
  • Founded: 1961
  • Team Size: 35000+
  • Industry: Pharmaceuticals

What This Means


This funding round demonstrates strong investor confidence in Mylan's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Pharmaceuticals sector continues to attract significant investment as companies innovate to meet evolving market demands. Mylan's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $18B valuation marks an important milestone for Mylan, positioning the company among notable players in the Pharmaceuticals industry.


Looking Ahead


With this new capital, Mylan is well-positioned to execute on its growth strategy and continue building innovative solutions in the Pharmaceuticals space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Mylan, visit their headquarters at 1000 Mylan Boulevard, Canonsburg, PA 15317.

Company Info

Headquarters
1000 Mylan Boulevard, Canonsburg, PA 15317
Founded
1961
Team Size
35000+

Topics

Fundraising(2912)Public(771)PharmaceuticalsMylan

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free